ECM2, a prognostic biomarker for lower grade glioma, serves as a potential novel target for immunotherapy
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
ECM2, a prognostic biomarker for lower grade glioma, serves as a potential novel target for immunotherapy
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
Volume 158, Issue -, Pages 106409
Publisher
Elsevier BV
Online
2023-03-29
DOI
10.1016/j.biocel.2023.106409
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Sperm Autoantigenic Protein 17 Predicts the Prognosis and the Immunotherapy Response of Cancers: A Pan-Cancer Analysis
- (2022) Zewei Tu et al. Frontiers in Immunology
- Growth differentiation factor-15 overexpression promotes cell proliferation and predicts poor prognosis in cerebral lower-grade gliomas correlated with hypoxia and glycolysis signature
- (2022) Ying Wang et al. LIFE SCIENCES
- IDH-Mutant Low-grade Glioma: Advances in Molecular Diagnosis, Management, and Future Directions
- (2021) Antonio Dono et al. Current Oncology Reports
- Statistical considerations in clinical trial design with event‐free survival as the primary efficacy endpoint
- (2021) Tu Xu et al. PHARMACEUTICAL STATISTICS
- Chinese Glioma Genome Atlas (CGGA): A Comprehensive Resource with Functional Genomic Data from Chinese Gliomas
- (2021) Zheng Zhao et al. GENOMICS PROTEOMICS & BIOINFORMATICS
- The Multifunctional Role of EMP3 in the Regulation of Membrane Receptors Associated with IDH-Wild-Type Glioblastoma
- (2021) Antoni Andreu Martija et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Expression and Prognosis of Sperm-Associated Antigen 1 in Human Breast Cancer
- (2021) Shuangyan Lin et al. OncoTargets and Therapy
- Worse prognosis for IDH wild-type diffuse gliomas with larger residual biological tumor burden
- (2021) Hiroyuki Tatekawa et al. ANNALS OF NUCLEAR MEDICINE
- METTL7B is a novel prognostic biomarker of lower-grade glioma based on pan-cancer analysis
- (2021) Zhipeng Jiang et al. Cancer Cell International
- BCL7A as a novel prognostic biomarker for glioma patients
- (2021) Junhui Liu et al. Journal of Translational Medicine
- RUNX1 and REXO2 are associated with the heterogeneity and prognosis of IDH wild type lower grade glioma
- (2021) Haiwei Wang et al. Scientific Reports
- HOXA5 Is Recognized as a Prognostic-Related Biomarker and Promotes Glioma Progression Through Affecting Cell Cycle
- (2021) Fengqin Ding et al. Frontiers in Oncology
- Expression, methylation and prognostic feature of EMILIN2 in Low-Grade-Glioma
- (2021) Li-chong Wang et al. BRAIN RESEARCH BULLETIN
- A Novel Cancer Stemness-Related Signature for Predicting Prognosis in Patients with Colon Adenocarcinoma
- (2021) Wei Wang et al. Stem Cells International
- Cross-Talk of Focal Adhesion-Related Gene Defines Prognosis and the Immune Microenvironment in Gastric Cancer
- (2021) Deli Mao et al. Frontiers in Cell and Developmental Biology
- Transcription Factor Signatures May Predict the Prognosis and Status of the Immune Microenvironment of Primary Lower-Grade Gliomas
- (2021) Peidong Liu et al. International Journal of General Medicine
- Diffuse gliomas to date and beyond 2016 WHO Classification of Tumours of the Central Nervous System
- (2020) Hiromi Onizuka et al. International Journal of Clinical Oncology
- MOB2 suppresses GBM cell migration and invasion via regulation of FAK/Akt and cAMP/PKA signaling
- (2020) Ke Jiang et al. Cell Death & Disease
- Single-cell transcriptomic architecture and intercellular crosstalk of human intrahepatic cholangiocarcinoma
- (2020) Min Zhang et al. JOURNAL OF HEPATOLOGY
- MGMT genomic rearrangements contribute to chemotherapy resistance in gliomas
- (2020) Barbara Oldrini et al. Nature Communications
- Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
- (2019) Xin Wang et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- The management of low-grade gliomas in adults
- (2019) Ramin A. Morshed et al. Journal of Neurosurgical Sciences
- Emerging roles of ECM remodeling processes in cancer
- (2019) Vishnu Mohan et al. SEMINARS IN CANCER BIOLOGY
- An independently validated survival nomogram for lower-grade glioma
- (2019) Haley Gittleman et al. NEURO-ONCOLOGY
- JAK-STAT Signaling: A Double-Edged Sword of Immune Regulation and Cancer Progression
- (2019) Katie L. Owen et al. Cancers
- Mining TCGA database for genes of prognostic value in glioblastoma microenvironment
- (2018) Di Jia et al. Aging-US
- Effect of ECM2 expression on bovine skeletal muscle-derived satellite cell differentiation
- (2018) Chang Liu et al. CELL BIOLOGY INTERNATIONAL
- Glioma infiltration and extracellular matrix: key players and modulators
- (2018) Valéria Pereira Ferrer et al. GLIA
- WHO 2016 Classification of gliomas
- (2018) P. Wesseling et al. NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY
- GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses
- (2017) Zefang Tang et al. NUCLEIC ACIDS RESEARCH
- Bioinformatic profiling identifies an immune-related risk signature for glioblastoma
- (2016) Wen Cheng et al. NEUROLOGY
- Management of patients with recurrence of diffuse low grade glioma
- (2015) Brian V. Nahed et al. JOURNAL OF NEURO-ONCOLOGY
- Maintaining Tissue Homeostasis: Dynamic Control of Somatic Stem Cell Activity
- (2011) Benoit Biteau et al. Cell Stem Cell
- Sperm-associated Antigens as Targets for Cancer Immunotherapy
- (2010) Karīna Siliņa et al. JOURNAL OF IMMUNOTHERAPY
- Glioma cancer stem cells induce immunosuppressive macrophages/microglia
- (2010) Adam Wu et al. NEURO-ONCOLOGY
- Dexamethasone inhibits camptothecin-induced apoptosis in C6-glioma via activation of Stat5/Bcl-xL pathway
- (2009) Yi-Hua Qian et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Constitutively Activated STAT3 Frequently Coexpresses with Epidermal Growth Factor Receptor in High-Grade Gliomas and Targeting STAT3 Sensitizes Them to Iressa and Alkylators
- (2008) H.-W. Lo et al. CLINICAL CANCER RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search